These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 2965692)
1. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets. Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692 [TBL] [Abstract][Full Text] [Related]
2. Selective suppression of the generation of anti-tumor L3T4+ but not of Lyt-2+ T cell-mediated immunity in the tumor-bearing state. Sano H; Sato S; Shima J; Tada T; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1988 Jul; 79(7):857-65. PubMed ID: 3139599 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset. Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511 [TBL] [Abstract][Full Text] [Related]
4. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. Sugihara S; Izumi Y; Yoshioka T; Yagi H; Tsujimura T; Tarutani O; Kohno Y; Murakami S; Hamaoka T; Fujiwara H J Immunol; 1988 Jul; 141(1):105-13. PubMed ID: 2967864 [TBL] [Abstract][Full Text] [Related]
5. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity. Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830 [TBL] [Abstract][Full Text] [Related]
6. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo. Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736 [TBL] [Abstract][Full Text] [Related]
7. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells. Barker E; Mokyr MB Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626 [TBL] [Abstract][Full Text] [Related]
8. Effects of anti-Lyt-2 and anti-L3T4 monoclonal antibodies on the function of cytotoxic T lymphocyte/helper T lymphocyte hybrid T cell clones. Havran WL; Fitch FW J Immunol; 1988 Sep; 141(6):1808-12. PubMed ID: 2459190 [TBL] [Abstract][Full Text] [Related]
9. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091 [TBL] [Abstract][Full Text] [Related]
10. Antibodies to the L3T4 and Lyt-2 molecules interfere with antigen receptor-driven activation of cloned murine T cells. Moldwin RL; Havran WL; Nau GJ; Lancki DW; Kim DK; Fitch FW J Immunol; 1987 Aug; 139(3):657-64. PubMed ID: 2955046 [TBL] [Abstract][Full Text] [Related]
11. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma. Chou T; Shu S J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448 [TBL] [Abstract][Full Text] [Related]
13. Role of L3T4 antigen in the activation of various functions of Lyt-1+2- T cells against vaccinia virus. Aoyama A; Yoshioka T; Sato S; Mizushima Y; Ogata M; Ueda S; Kato S; Fujiwara H; Hamaoka T Microbiol Immunol; 1986; 30(8):799-810. PubMed ID: 2946922 [TBL] [Abstract][Full Text] [Related]
14. Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. Kruisbeek AM; Mond JJ; Fowlkes BJ; Carmen JA; Bridges S; Longo DL J Exp Med; 1985 May; 161(5):1029-47. PubMed ID: 3921649 [TBL] [Abstract][Full Text] [Related]
15. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of helper function with anti-Lyt-2 or anti-L3T4 monoclonal antibodies depending on stimulating antigens. Guimezanes A; Schmitt-Verhulst AM Eur J Immunol; 1985 Dec; 15(12):1187-91. PubMed ID: 2935405 [TBL] [Abstract][Full Text] [Related]
17. Differences in the phenotypes of cells mediating anti-tumour immunity at various stages of tumour progression in mice. Dent LA; Spencer LK; Attridge S; Finlay-Jones JJ Immunol Cell Biol; 1989 Dec; 67 ( Pt 6)():403-12. PubMed ID: 2696727 [TBL] [Abstract][Full Text] [Related]
18. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Müller I; Cobbold SP; Waldmann H; Kaufmann SH Infect Immun; 1987 Sep; 55(9):2037-41. PubMed ID: 3114143 [TBL] [Abstract][Full Text] [Related]
19. Relationship among function, phenotype, and specificity in primary allospecific T cell populations: identification of phenotypically identical but functionally distinct primary T cell subsets that differ in their recognition of MHC class I and class II allodeterminants. Golding H; Mizuochi T; McCarthy SA; Cleveland CA; Singer A J Immunol; 1987 Jan; 138(1):10-7. PubMed ID: 2946773 [TBL] [Abstract][Full Text] [Related]
20. Contrasuppressor cells that break oral tolerance are antigen-specific T cells distinct from T helper (L3T4+), T suppressor (Lyt-2+), and B cells. Kitamura K; Kiyono H; Fujihashi K; Eldridge JH; Green DR; McGhee JR J Immunol; 1987 Nov; 139(10):3251-9. PubMed ID: 3500210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]